Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy
Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol te...
Ausführliche Beschreibung
Autor*in: |
Yeongcheol Cheong [verfasserIn] Hidetoshi Katsuno [verfasserIn] Hiroshi Matsuoka [verfasserIn] Masahiro Mizuno [verfasserIn] Tomoyoshi Endo [verfasserIn] Tadahiro Kamiya [verfasserIn] Yosuke Tajima [verfasserIn] Keigo Ashida [verfasserIn] Yoshikazu Koide [verfasserIn] Koji Masumori [verfasserIn] Harunobu Sato [verfasserIn] Tsunekazu Hanai [verfasserIn] Kotaro Maeda [verfasserIn] Ichiro Uyama [verfasserIn] Junichiro Hiro [verfasserIn] Koichi Suda [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Fujita Medical Journal - Fujita Medical Society, 2020, 8(2022), 3, Seite 88-95 |
---|---|
Übergeordnetes Werk: |
volume:8 ; year:2022 ; number:3 ; pages:88-95 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.20407/fmj.2021-011 |
---|
Katalog-ID: |
DOAJ020026404 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ020026404 | ||
003 | DE-627 | ||
005 | 20230307034141.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.20407/fmj.2021-011 |2 doi | |
035 | |a (DE-627)DOAJ020026404 | ||
035 | |a (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a R5-920 | |
100 | 0 | |a Yeongcheol Cheong |e verfasserin |4 aut | |
245 | 1 | 0 | |a Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. | ||
650 | 4 | |a menthol | |
650 | 4 | |a oxaliplatin-induced neuropathy | |
650 | 4 | |a opn | |
650 | 4 | |a oxaliplatin | |
653 | 0 | |a Medicine (General) | |
700 | 0 | |a Hidetoshi Katsuno |e verfasserin |4 aut | |
700 | 0 | |a Hiroshi Matsuoka |e verfasserin |4 aut | |
700 | 0 | |a Masahiro Mizuno |e verfasserin |4 aut | |
700 | 0 | |a Tomoyoshi Endo |e verfasserin |4 aut | |
700 | 0 | |a Tadahiro Kamiya |e verfasserin |4 aut | |
700 | 0 | |a Yosuke Tajima |e verfasserin |4 aut | |
700 | 0 | |a Keigo Ashida |e verfasserin |4 aut | |
700 | 0 | |a Yoshikazu Koide |e verfasserin |4 aut | |
700 | 0 | |a Koji Masumori |e verfasserin |4 aut | |
700 | 0 | |a Harunobu Sato |e verfasserin |4 aut | |
700 | 0 | |a Tsunekazu Hanai |e verfasserin |4 aut | |
700 | 0 | |a Kotaro Maeda |e verfasserin |4 aut | |
700 | 0 | |a Ichiro Uyama |e verfasserin |4 aut | |
700 | 0 | |a Junichiro Hiro |e verfasserin |4 aut | |
700 | 0 | |a Koichi Suda |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Fujita Medical Journal |d Fujita Medical Society, 2020 |g 8(2022), 3, Seite 88-95 |w (DE-627)1692251066 |x 21897255 |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2022 |g number:3 |g pages:88-95 |
856 | 4 | 0 | |u https://doi.org/10.20407/fmj.2021-011 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 |z kostenfrei |
856 | 4 | 0 | |u https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2189-7247 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2189-7255 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 8 |j 2022 |e 3 |h 88-95 |
author_variant |
y c yc h k hk h m hm m m mm t e te t k tk y t yt k a ka y k yk k m km h s hs t h th k m km i u iu j h jh k s ks |
---|---|
matchkey_str |
article:21897255:2022----::salsmnoteetotsaalnclvlainehdooa |
hierarchy_sort_str |
2022 |
callnumber-subject-code |
R |
publishDate |
2022 |
allfields |
10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95 |
spelling |
10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95 |
allfields_unstemmed |
10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95 |
allfieldsGer |
10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95 |
allfieldsSound |
10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95 |
language |
English |
source |
In Fujita Medical Journal 8(2022), 3, Seite 88-95 volume:8 year:2022 number:3 pages:88-95 |
sourceStr |
In Fujita Medical Journal 8(2022), 3, Seite 88-95 volume:8 year:2022 number:3 pages:88-95 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) |
isfreeaccess_bool |
true |
container_title |
Fujita Medical Journal |
authorswithroles_txt_mv |
Yeongcheol Cheong @@aut@@ Hidetoshi Katsuno @@aut@@ Hiroshi Matsuoka @@aut@@ Masahiro Mizuno @@aut@@ Tomoyoshi Endo @@aut@@ Tadahiro Kamiya @@aut@@ Yosuke Tajima @@aut@@ Keigo Ashida @@aut@@ Yoshikazu Koide @@aut@@ Koji Masumori @@aut@@ Harunobu Sato @@aut@@ Tsunekazu Hanai @@aut@@ Kotaro Maeda @@aut@@ Ichiro Uyama @@aut@@ Junichiro Hiro @@aut@@ Koichi Suda @@aut@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
1692251066 |
id |
DOAJ020026404 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ020026404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307034141.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.20407/fmj.2021-011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ020026404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Yeongcheol Cheong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">menthol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxaliplatin-induced neuropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">opn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxaliplatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hidetoshi Katsuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Matsuoka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masahiro Mizuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomoyoshi Endo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tadahiro Kamiya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yosuke Tajima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Keigo Ashida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshikazu Koide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koji Masumori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harunobu Sato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tsunekazu Hanai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kotaro Maeda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ichiro Uyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Junichiro Hiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koichi Suda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Fujita Medical Journal</subfield><subfield code="d">Fujita Medical Society, 2020</subfield><subfield code="g">8(2022), 3, Seite 88-95</subfield><subfield code="w">(DE-627)1692251066</subfield><subfield code="x">21897255</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:88-95</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.20407/fmj.2021-011</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2189-7247</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2189-7255</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="h">88-95</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Yeongcheol Cheong |
spellingShingle |
Yeongcheol Cheong misc R5-920 misc menthol misc oxaliplatin-induced neuropathy misc opn misc oxaliplatin misc Medicine (General) Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy |
authorStr |
Yeongcheol Cheong |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1692251066 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
R5-920 |
illustrated |
Not Illustrated |
issn |
21897255 |
topic_title |
R5-920 Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy menthol oxaliplatin-induced neuropathy opn oxaliplatin |
topic |
misc R5-920 misc menthol misc oxaliplatin-induced neuropathy misc opn misc oxaliplatin misc Medicine (General) |
topic_unstemmed |
misc R5-920 misc menthol misc oxaliplatin-induced neuropathy misc opn misc oxaliplatin misc Medicine (General) |
topic_browse |
misc R5-920 misc menthol misc oxaliplatin-induced neuropathy misc opn misc oxaliplatin misc Medicine (General) |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Fujita Medical Journal |
hierarchy_parent_id |
1692251066 |
hierarchy_top_title |
Fujita Medical Journal |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1692251066 |
title |
Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy |
ctrlnum |
(DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 |
title_full |
Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy |
author_sort |
Yeongcheol Cheong |
journal |
Fujita Medical Journal |
journalStr |
Fujita Medical Journal |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
container_start_page |
88 |
author_browse |
Yeongcheol Cheong Hidetoshi Katsuno Hiroshi Matsuoka Masahiro Mizuno Tomoyoshi Endo Tadahiro Kamiya Yosuke Tajima Keigo Ashida Yoshikazu Koide Koji Masumori Harunobu Sato Tsunekazu Hanai Kotaro Maeda Ichiro Uyama Junichiro Hiro Koichi Suda |
container_volume |
8 |
class |
R5-920 |
format_se |
Elektronische Aufsätze |
author-letter |
Yeongcheol Cheong |
doi_str_mv |
10.20407/fmj.2021-011 |
author2-role |
verfasserin |
title_sort |
establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy |
callnumber |
R5-920 |
title_auth |
Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy |
abstract |
Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. |
abstractGer |
Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. |
abstract_unstemmed |
Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3 |
title_short |
Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy |
url |
https://doi.org/10.20407/fmj.2021-011 https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en https://doaj.org/toc/2189-7247 https://doaj.org/toc/2189-7255 |
remote_bool |
true |
author2 |
Hidetoshi Katsuno Hiroshi Matsuoka Masahiro Mizuno Tomoyoshi Endo Tadahiro Kamiya Yosuke Tajima Keigo Ashida Yoshikazu Koide Koji Masumori Harunobu Sato Tsunekazu Hanai Kotaro Maeda Ichiro Uyama Junichiro Hiro Koichi Suda |
author2Str |
Hidetoshi Katsuno Hiroshi Matsuoka Masahiro Mizuno Tomoyoshi Endo Tadahiro Kamiya Yosuke Tajima Keigo Ashida Yoshikazu Koide Koji Masumori Harunobu Sato Tsunekazu Hanai Kotaro Maeda Ichiro Uyama Junichiro Hiro Koichi Suda |
ppnlink |
1692251066 |
callnumber-subject |
R - General Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.20407/fmj.2021-011 |
callnumber-a |
R5-920 |
up_date |
2024-07-04T01:50:02.371Z |
_version_ |
1803611330182119424 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ020026404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307034141.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.20407/fmj.2021-011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ020026404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Yeongcheol Cheong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">menthol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxaliplatin-induced neuropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">opn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxaliplatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hidetoshi Katsuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Matsuoka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masahiro Mizuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomoyoshi Endo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tadahiro Kamiya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yosuke Tajima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Keigo Ashida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshikazu Koide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koji Masumori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harunobu Sato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tsunekazu Hanai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kotaro Maeda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ichiro Uyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Junichiro Hiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koichi Suda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Fujita Medical Journal</subfield><subfield code="d">Fujita Medical Society, 2020</subfield><subfield code="g">8(2022), 3, Seite 88-95</subfield><subfield code="w">(DE-627)1692251066</subfield><subfield code="x">21897255</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:88-95</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.20407/fmj.2021-011</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2189-7247</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2189-7255</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="h">88-95</subfield></datafield></record></collection>
|
score |
7.3996735 |